EMA and AMA Unite on Bundibugyo Ebola Response, Identifying Six Clinical Trial Candidates

With no authorised vaccines or treatments for Bundibugyo virus disease, EMA's Emergency Task Force (ETF) has moved into active developer engagement alongside the African Medicines Agency (AMA) and participating national regulatory authorities (NRAs), marking the first public health emergency in which EMA and the fully operational AMA have collaborated directly. For regulatory affairs teams working on filovirus countermeasures, the joint framework now defines both the candidate landscape and the clinical trial design expectations they will need to meet.

The trigger is the WHO Public Health Emergency of International Concern declared on 17 May 2026, covering the Bundibugyo virus outbreak in the Democratic Republic of the Congo and Uganda. Critically, existing Zaire Ebola virus countermeasures are considered unlikely to be effective against Bundibugyo, requiring purpose-built development programmes rather than label extensions or repurposing of authorised products.

The ETF's horizon scanning has surfaced six candidates now under active discussion with developers, academia, and funders. Three vaccine candidates have been identified: an rVSV-based Bundibugyo vaccine, a ChAdOx1 modified adenovirus platform vaccine, and an mRNA vaccine. Three treatment or prophylaxis candidates are also in scope: MBP-134 (a dual monoclonal antibody combination), remdesivir, and maftivimab, alongside obeldesivir for post-exposure prophylaxis.

Clinical trial design discussions are expected to span the full development arc, from early-phase safety studies through pivotal trials, and will address prophylaxis, post-exposure prophylaxis, and treatment across all age groups. The collaborative structure draws on prior AVAREF joint review experience from previous Ebola outbreaks, providing a procedural foundation that regulators and sponsors can reference when structuring submissions and protocol consultations.

For regulatory affairs leads, the operative signal is that ICH-aligned scientific rigour remains the baseline even under emergency timelines. The joint ETF-AMA framework is designed to compress review cycles without relaxing evidentiary standards, meaning sponsors will need robust adaptive trial designs and pre-agreed statistical frameworks before engaging. Developers not yet in contact with the ETF should note that candidate selection discussions are already underway; late engagement risks misalignment with the regulatory criteria being established now.

The European Centre for Disease Prevention and Control currently assesses infection risk for EU/EEA residents as very low, but that epidemiological status does not affect the regulatory development timeline, which is being driven by outbreak geography and the absence of authorised countermeasures.

The pace at which the ETF and AMA formalise shared clinical trial criteria for Bundibugyo candidates will set a measurable benchmark for how quickly investigational products can enter pivotal trials under the joint emergency framework.

Source: European Medicines Agency (EMA) via ema.europa.eu, 3 June 2026.